Skip to main content
Premium Trial:

Request an Annual Quote

Public-Private Data Science Collaboration to ID Alzheimer's, Other Neurodegenerative Risk Factors

NEW YORK – Invicro and Data Tecnica International will collaborate with the National Institutes of Health's Center for Alzheimer's and Related Dementias to develop a curated collection of genomic and imaging data to improve precision medicine approaches for these conditions.

The collaboration aims to help CARD scientists better stratify patients by risk factors and predict their disease progression, enabling better patient monitoring and treatment, as well as supporting early clinical trial enrollments. The curated dataset may also improve researchers' understanding of how patients' underlying genetic makeup and medical history can affect the prediction, treatment, and prevention of neurodegenerative disorders.

The collaborators expect that by integrating changes in imaging and cognition, they might better define the neurodegenerative disease spectrum and how these disorders progress in individuals and patient groups. 

This, in turn, could enhance the assessment and efficacy of potential neurodegenerative disorder therapies.

"Alzheimer's and related dementias are multi-system and remarkably complex. To better understand these disorders, we need to take a comprehensive, multi-modal approach, integrating and analyzing large datasets of multiomics and imaging," Faraz Faghri, senior scientific data consultant and computer science lead at DTi working on contract with CARD, said in a statement.

Invicro is involved in several other biomarker search collaborations, including with Yale University, with whom they are developing an amplification-free protein detection method called Quanticell.